Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sarepta Therapeutics

19.03
+1.719.87%
Post-market: 19.050.0200+0.11%19:36 EDT
Volume:5.80M
Turnover:109.10M
Market Cap:1.87B
PE:-7.35
High:19.36
Open:17.49
Low:17.35
Close:17.32
Loading ...

Stock Track | Sarepta Therapeutics Plunges 25.93% as FDA Appoints Gene Therapy Critic to Key Position

Stock Track
·
07 May

U.S.-Listed Shares of CRISPR Therapeutics Fall 10.3%, Sarepta Therapeutics Fall 20.2%

THOMSON REUTERS
·
07 May

Gene Therapy Makers Fall After US FDA Names Oncologist Vinay Prasad as Top Vaccine Official

THOMSON REUTERS
·
07 May

H.C. Wainwright Sticks to Their Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
06 May

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution

StockStory
·
01 May

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now

Insider Monkey
·
30 Apr

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Zacks
·
29 Apr

Press Release: Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Dow Jones
·
22 Apr

BRIEF-Sarepta Therapeutics To Announce First Quarter 2025 Financial Results

Reuters
·
22 Apr

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

THOMSON REUTERS
·
22 Apr

Sarepta Therapeutics Inc : Leerink Partners Cuts Target Price to $150 From $200

THOMSON REUTERS
·
22 Apr

Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
21 Apr

Sarepta price target lowered to $110 from $182 at Piper Sandler

TIPRANKS
·
21 Apr

U.S. RESEARCH ROUNDUP-Lowe's, Netflix, Vulcan Materials

Reuters
·
21 Apr

Sarepta Therapeutics Inc : Piper Sandler Cuts Target Price to $110 From $182

THOMSON REUTERS
·
21 Apr

Exploring 3 High Growth Tech Stocks In The US Market

Simply Wall St.
·
19 Apr

BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating

MT Newswires Live
·
17 Apr

Sarepta Therapeutics Price Target Maintained With a $75.00/Share by HC Wainwright & Co.

Dow Jones
·
16 Apr

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

Zacks
·
16 Apr

Cautious Hold Rating on Sarepta Therapeutics Amid Limited LGMD Market and ELEVIDYS Uncertainties

TIPRANKS
·
16 Apr